Silexion Therapeutics Corp reported the issuance of 450,000 ordinary shares on September 15, 2025, resulting from converting $1.8 million of a Sponsor Convertible Note, and affirmed compliance with Nasdaq's equity requirements, with total shareholders' equity now at approximately $9.41 million, up from $0.1 million in June 2025.